GSTM1 and codon 72 P53 polymorphism in multiple myeloma.

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Glutathione S-transferase (GST) enzymes, encoded by GSTM1 and GSTT1 genes, detoxify cytotoxic agents.
• The P53 tumor suppressor gene has a common polymorphism at amino acid position 72, resulting in arginine (A) or proline (P) variants with distinct functions.
• The association between GSTM1, GSTT1, and P53 genotypes and multiple myeloma (MM) risk remains largely unexplored.

Purpose of the Study:

• To investigate the potential association between GSTM1, GSTT1, and P53 genotypes and the risk of developing multiple myeloma (MM) in a Brazilian population.
• To explore if these genetic variations influence disease progression in MM patients.

Main Methods:

• Genomic DNA was collected from 106 MM patients and 230 healthy controls.
• Polymerase chain reaction (PCR)-based methods were employed to determine the genotypes of GSTM1, GSTT1, and P53.
• Statistical analyses were performed to compare genotype frequencies and disease risk between patients and controls, and across different disease stages.

Main Results:

• No significant differences in the frequencies of GSTM1, GSTT1, and P53 genotypes were observed between MM patients and controls.
• Individuals with specific genotypes, including GSTM1 null and P53 PP+AP, showed an increased prevalence in advanced Stage III MM compared to Stages I+II.
• The combined GSTM1 null and P53 PP+AP genotypes were significantly more frequent in Stage III MM patients.

Conclusions:

• GSTM1, GSTT1, and P53 genotypes do not appear to be risk factors for developing multiple myeloma (MM).
• The study identified a potential role for the variant codon 72 P53 allele and the absence of the GSTM1 detoxification pathway in the progression of MM.
• These findings suggest that while not affecting initial risk, certain genetic profiles may influence disease advancement in the Brazilian population.